• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·4543.T
Share

Terumo Corporation Stocks

¥ 2273.5Last Updated 28.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

¥ 19.48B

¥ 2273.5
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4543.T is 3056 and suggests 41.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 22:21

Apple's market capitalization reached $5 trillion for the first time

28.07.2026 22:17

The EU is preparing a record-breaking package of sanctions against more than 1,600 Russian companies — media reports

28.07.2026 22:14

Boeing's loss was worse than expected. Why are its shares rising?

28.07.2026 21:58

U.S. senators have agreed on “severe sanctions” against Russia. What happens next?

28.07.2026 21:28

Apple Is Preparing for a Breakthrough in the Smart Home Market — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026